Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Historical Holders from Q2 2019 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
AKRO
Shares outstanding
79,376,583
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
91,445,783
Holdings value
$4,342,086,695
% of all portfolios
0.01%
Share change
-751,248
Value change
-$45,117,892
Average buys %
+0%
Average sells %
-0%
Number of holders
259
Price from insider filings
$21.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GENERAL ATLANTIC, L.P. 8.4% $278,656,049 6,796,489 General Atlantic, L.P. 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.9% -6.7% $298,188,881 -$21,757,757 6,280,305 -6.8% JANUS HENDERSON GROUP PLC 30 Sep 2025
RTW INVESTMENTS, LP 7.3% -25% $304,707,219 -$51,180,398 5,873,308 -14% RTW Investments, LP 30 Jun 2025
Deep Track Capital, LP 5.5% $208,910,680 4,400,000 Deep Track Capital, LP 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 5.3% +25% $201,878,360 +$39,974,124 4,251,861 +25% Wellington Management Group LLP 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.8% $180,902,408 3,810,076 T. Rowe Price Associates, Inc. 30 Sep 2025
As of 30 Sep 2025, Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 259 institutional shareholders filing 13F forms. They hold 91,445,783 shares .

Top 25 institutional shareholders own 85% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 7.9% 6,280,305 -6.8% 0.14% $298,242,505
GENERAL ATLANTIC, L.P. 7.2% 5,733,989 0% 8.2% $272,249,798
BlackRock, Inc. 7.2% 5,702,634 -1.3% 0% $270,761,064
RTW INVESTMENTS, LP 6.9% 5,477,561 0% 3.2% $260,074,596
VANGUARD GROUP INC 5.7% 4,526,920 -0.06% 0% $214,938,161
WELLINGTON MANAGEMENT GROUP LLP 5.4% 4,251,861 +25% 0.04% $201,878,361
Deep Track Capital, LP 5% 4,000,978 +31% 5.3% $189,966,435
Avoro Capital Advisors LLC 5% 3,955,555 +13% 2.4% $187,809,751
PRICE T ROWE ASSOCIATES INC /MD/ 4.8% 3,809,859 -16% 0.02% $180,893,000
STATE STREET CORP 4.3% 3,414,306 +24% 0.01% $162,111,249
Bellevue Group AG 3% 2,389,314 +20% 2.4% $113,444,628
ALKEON CAPITAL MANAGEMENT LLC 2.3% 1,850,934 0% 0.4% $87,882,346
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,785,586 +3.7% 0.01% $84,792,838
ALLIANCEBERNSTEIN L.P. 2.1% 1,689,629 +10% 0.03% $80,223,585
Point72 Asset Management, L.P. 2.1% 1,663,339 -39% 0.17% $78,975,351
BANK OF AMERICA CORP /DE/ 1.6% 1,297,438 -1.7% 0% $61,602,356
MARSHALL WACE, LLP 1.5% 1,217,044 -14% 0.06% $57,785,250
Logos Global Management LP 1.5% 1,200,000 0% 5.6% $56,976,000
PERCEPTIVE ADVISORS LLC 1.4% 1,135,766 +24% 1.6% $53,926,170
FMR LLC 1.4% 1,079,657 +16% 0% $51,262,104
Polar Capital Holdings Plc 1.3% 1,058,776 0.24% $50,270,684
Holocene Advisors, LP 1.3% 1,055,186 -1.9% 0.12% $50,100,231
Pictet Asset Management Holding SA 1.2% 926,441 -6.1% 0.04% $43,997,202
GOLDMAN SACHS GROUP INC 1.1% 855,766 +12% 0.01% $40,631,770
DIMENSIONAL FUND ADVISORS LP 1% 810,568 +41% 0.01% $38,486,653

Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 0 $0 -$858,331 0
2025 Q3 91,445,783 $4,342,086,695 -$45,117,892 $47.48 259
2025 Q2 92,131,681 $4,916,497,064 +$352,115,121 $53.36 253
2025 Q1 86,154,634 $3,503,843,061 +$531,433,647 $40.48 238
2024 Q4 74,174,925 $2,063,406,098 -$8,506,883 $27.82 188
2024 Q3 73,002,070 $2,094,264,742 +$38,454,830 $28.69 167
2024 Q2 71,810,586 $1,684,723,283 -$32,810,693 $23.46 152
2024 Q1 73,087,900 $1,845,988,959 +$363,844,050 $25.26 171
2023 Q4 58,426,478 $1,364,286,476 -$103,406,827 $23.35 153
2023 Q3 56,757,185 $2,870,716,263 +$69,098,588 $50.58 178
2023 Q2 56,372,656 $2,631,606,875 +$394,199,729 $46.69 156
2023 Q1 48,070,649 $1,839,011,256 -$64,149,034 $38.26 155
2022 Q4 48,581,649 $2,661,931,733 +$138,143,044 $54.80 159
2022 Q3 46,589,695 $1,586,331,269 +$490,029,839 $34.05 142
2022 Q2 34,862,359 $329,587,739 -$12,722,696 $9.45 107
2022 Q1 35,141,546 $498,682,069 -$2,941,499 $14.19 98
2021 Q4 35,317,227 $746,760,550 +$3,654,957 $21.15 96
2021 Q3 27,981,387 $625,678,377 +$7,096,019 $22.35 102
2021 Q2 27,584,397 $684,200,429 -$121,336,833 $24.81 94
2021 Q1 31,507,544 $913,643,371 +$20,106,775 $29.01 109
2020 Q4 30,844,129 $813,955,792 +$45,233,337 $25.80 94
2020 Q3 28,988,756 $892,491,434 +$220,301,852 $30.79 103
2020 Q2 21,827,155 $543,916,299 -$2,246,835 $24.92 75
2020 Q1 22,025,386 $466,923,796 +$63,234,074 $21.20 66
2019 Q4 19,000,379 $421,605,474 +$18,157,481 $22.19 57
2019 Q3 12,742,598 $288,264,741 +$54,821,814 $22.75 54
2019 Q2 10,674,595 $204,526,000 +$204,526,000 $19.15 48